In today’s recent session, 1.72 million shares of the Marinus Pharmaceuticals Inc (NASDAQ:MRNS) have been traded, and its beta is 1.20. Most recently the company’s share price was $1.46, and it changed around $0.08 or 5.80% from the last close, which brings the market valuation of the company to $79.77M. MRNS at last check was trading at a discount to its 52-week high of $11.26, offering almost -671.23% off that amount. The share price’s 52-week low was $1.11, which indicates that the recent value has risen by an impressive 23.97% since then. We note from Marinus Pharmaceuticals Inc’s average daily trading volume that its 3-month average coming to 1.61 million.
Marinus Pharmaceuticals Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.55. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended MRNS as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. Marinus Pharmaceuticals Inc is expected to report earnings per share of -$0.66 for the current quarter.
Marinus Pharmaceuticals Inc (NASDAQ:MRNS) trade information
Instantly MRNS has been showing a green trend so far today with a performance of 5.80% on intraday trading today. The performance over the last five days has remained in the green territory. The company’s shares are currently down -86.57% year-to-date, but still up 12.31% over the last five days. On the other hand, Marinus Pharmaceuticals Inc (NASDAQ:MRNS) is -83.80% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $4.67, which translates to bulls needing to increase their stock price by 68.74% from its current value. Analyst projections state that MRNS is forecast to be at a low of $2 and a high of $9.
Marinus Pharmaceuticals Inc (MRNS) estimates and forecasts
Marinus Pharmaceuticals Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -78.40 percent over the past six months and at a 15.21% annual growth rate that is well above the industry average of 10.20%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 1.50% in revenue this quarter, and will report an increase of 1.60% in the next quarter. The year-over-year growth rate is expected to be 31.80%, up from the previous year.
Consensus estimates provided by 11 financial analysts predict the company will bring in an average of $9.12 million in revenue for the current quarter. 11 analysts expect Marinus Pharmaceuticals Inc to make $9.59 million in revenue for the quarter ending Jun 2024. The company’s sales for the same quarters a year ago were $10.38 million and $6.08 million respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -12.10%. Forecasts for the next quarter put sales growth at 57.70%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 6.04%. Marinus Pharmaceuticals Inc earnings are expected to increase by 16.53% in 2024, but the outlook is positive 20.00% per year for the next five years.
